Overweight and obesity are not associated with worse clinical outcomes in COVID-19 patients treated with fixed-dose 6 mg dexamethasone

OBJECTIVE: A fixed 6 mg dexamethasone dose for 10 days is the standard treatment for all hospitalised COVID-19 patients who require supplemental oxygen. Yet, the pharmacokinetic properties of dexamethasone can lead to diminishing systemic dexamethasone exposure with increasing body mass index (BMI)....

Descripción completa

Detalles Bibliográficos
Autores principales: Wittermans, Esther, Grutters, Jan C., Moeniralam, Hazra S., Ocak, Gurbey, Paul Voorn, G., Bos, Willem Jan W., van de Garde, Ewoudt M. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388353/
https://www.ncbi.nlm.nih.gov/pubmed/35982120
http://dx.doi.org/10.1038/s41366-022-01204-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388353/
https://www.ncbi.nlm.nih.gov/pubmed/35982120
http://dx.doi.org/10.1038/s41366-022-01204-1

Ejemplares similares